IRCT20121021011192N15 IRCT 2023-06-21 Shahid Beheshti University of Medical Sciences Effect of alphapinen addition to quadruple therapy for the eradication of Helicobacter pylori gastrointestinal infectious Effect of alphapinen addition to quadruple therapy for the eradication of Helicobacter pylori gastrointestinal infectious 2023-07-23 anticipated 76 Complete https://irct.ir/trial/70229 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: 1:1 randomization, centralized web-based randomization and according to the entry and exit criteria, through random allocation by balanced block method, individuals are divided into two groups of control and experimental. Using Random Sequence Generator, groups are created and people are placed in one of these two groups based on the reference sequence, Blinding description: Participants, principle investigator, healthcare providers (Physicians, nurses) who care for participants during the trial, data collectors and outcome assessors all are blinded by providing placebo capsules in same size, shape color, odor and package with capsules of alphapinen which organized just by one responsible co-researcher has no involvement in running study. 3 Infectious with Helicobacter pylori. Intervention 1: Intervention group: Addition ofalphapinen orally 10 mg/d to eradication regimen of Helicobacter pylori for 2 weeks. Intervention 2: Control group: Addition of alphapinen placebo 1 capsule per day orally to eradication regimen of Helicobacter pylori for 2 weeks. Yes - There is a plan to make this available What will be shared: All data can be shared after deidentified When: starting in ِJuly 2024 To whom: only available for people working in academic institutions Conditions: with written consent Where to obtain: Sending email to: m_abbasi@sbmu.ac.ir How to obtain: Sending email to: m_abbasi@sbmu.ac.ir Comments: